U.S. DTC Genetic Testing Market size to exceed USD 890mn by 2025
Published Date: October 1, 2019 Authors: Sumant Ugalmugle
U.S. DTC Genetic Testing Market size is set to exceed USD 890 million by 2025; according to a new research report by Global Market Insights, Inc.
Rising adoption and demand for DTC genetic tests coupled with technological advancements will drive the U.S. Direct-to-Consumer genetic testing market genetic testing market. Numerous advantages of personalized medications including monitoring of genetic and patient’s unique molecular profile to enhance patient’s health will prove beneficial for the business growth. Direct-to-Consumer genetic testing helps in formulation of personalized medication for the patients suffering from melanoma, breast cancer as well as other genetic diseases. Increasing prevalence of these diseases will generate huge demand for direct-to-consumer genetic tests over the analysis period.
Increasing incidence of genetic disorders especially in North America will escalate the demand for direct-to-consumer genetic testing. High prevalence of genetic diseases such as achondroplasia, breast cancer and colorectal cancer and others will positively impact the business growth over coming years. According to the data published on American Cancer Society, Inc. in 2019, colorectal cancer is the 3rd frequent cancer diagnosed in women and men in the U.S. FDA has approved a direct-to-consumer genetic test for a hereditary form of colorectal cancer by 23andMe. Increasing prevalence of such diseases coupled with advent of direct-to-consumer genetic tests will augment the industry growth. However, defects in the genetic tests may impede U.S. direct-to-consumer genetic testing market growth during the analysis timeframe.
Get more details on this report - Request Free Sample PDF
Predictive testing segment of U.S. direct-to-consumer genetic testing market was valued around USD 50 million in 2018 owing to advent of technologically upgraded platforms to perform genome analysis. Predicative testing is a type of presymptomatic testing that enables chances of acquiring the disease before onset of symptoms. This allows effective management of the condition. These factors should propel the predictive testing segment growth in years to come.
Single nucleotide polymorphism (SNP) chips segment U.S. DTC genetic testing market accounted for around 50% revenue share in 2018 and will show robust growth from 2018 to 2025. Majority of the companies that provide DTC genetic tests utilize SNP genotyping technology enabling accurate classification of genomes that helps in detection of various genetic diseases such as sickle cell anemia. Thus, increasing demand for (SNP) chips will fosters the At-home genetic testing market growth in near future.
Browse key industry insights spread across 56 pages with 5 market data tables & 7 figures & charts from the report, “U.S. Direct-To-Consumer Genetic Testing Market Size By Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomics Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS)), Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents:
Prominent industry players functioning in U.S. DTC genetic testing market include Pathway Genomics, Ancestry, 23andMe, Color Genomics, FamilytreeDNA, Identigene, Helix OpCo, EasyDNA, Full Genome, Living DNA, Karmagenes, and MyHeritage. Several initiatives undertaken by market players such as mergers and collaborations to sustain in the business will prove beneficial for industry growth. For instance, in October 2018, 23andme received first U.S. FDA approval for de novotechnology used in pharmacogenomic tests. Such new product approvals will enable company to extend its offerings in direct-to-consumer genetic testing business.
U.S. Direct-To-Consumer Genetic Testing market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2014 to 2025, for the following segments:
U.S. DTC Genetic Testing Market, By Test Type, 2014-2025 (USD Million)
- Carrier testing
- Predictive testing
- Ancestry & relationship testing
- Nutrigenomics testing
U.S. DTC Genetic Testing Market, By Technology, 2014-2025 (USD Million)
- Targeted analysis
- Single nucleotide polymorphism (SNP) chips
- Whole genome sequencing (WGS)